InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
March 06 2009 - 6:47AM
PR Newswire (US)
- Company Receives Allowance of Patent Claims in the U.S. and in
India - BRITISH COLUMBIA, Canada, March 6 /PRNewswire-FirstCall/ --
InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE:
IXS; http://www.ixsbio.com/), a drug development company
commercializing the next generation of monoclonal antibodies based
on its Dynamic Cross Linking (DXL(TM)) technology, announces that
it has received a notice of allowance on patent claims in the
United States (Serial No. 11/119,404) and a patent grant in India
(National Phase Application No. 2424/CHENP/2005) further expanding
its protection of InNexus' DXL(TM) technology. Speaking on today's
announcement, InNexus Chairman and CEO, Jeff Morhet said, "DXL(TM)
antibodies that penetrate directly into cells, is an exciting
achievement for InNexus and our industry. As we've continued to
expand our patent portfolio and discover new technologies to
develop products, the team has aggressively pursued patent
protection for our novel inventions. Patents are the currency of
our industry and a driver for enhanced value for our shareholders
and potential use of these cell penetrating DXL(TM) antibodies
represents another frontier for the use of antibodies for
therapeutic and diagnostic applications." Dr. Thomas Kindt, Chief
Scientific Officer of InNexus said, "The claims in these patents
are directed toward the addition of membrane transport sequences to
DXL antibodies, which facilitate penetration of DXL(TM) antibodies
into cancer cells. The ability to direct our DXL(TM) antibodies to
intracellular targets by the addition of a membrane transport
sequence, imparts great therapeutic potential in a number of
applications. The patents and applications also include coverage
for new molecules and products of InNexus. We like to say We Build
Better Antibodies and today, we demonstrated that once again."
InNexus also announced that Jeff Morhet, Chairman and CEO, was
recently highlighted and quoted in an article titled "JAMA study
casts cloud over biologic safety" in the January 2009 issue of
Nature Biotechnology. A copy of the article can be downloaded at:
http://www.nature.com/nbt/journal/v27/n1/pdf/nbt0109-11.pdf. Nature
Biotechnology is a widely read academic journal published by Nature
Publishing Group, a division of Macmillan Publishers Ltd., covering
the science and business of biotechnology. About InNexus InNexus is
a drug development company commercializing the next generation of
monoclonal antibodies based on its DXL(TM) technology, which
improves the potency of existing antibody products while opening
new markets and disease applications. DXL(TM) antibodies utilize
unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal
management based in Scottsdale, Arizona on the campus of Mayo
Clinic and has its own in-house developmental facilities. These
development resources provide validation of protein and peptide
discoveries, enabling InNexus (and its strategic partners) to
advance novel drug therapeutics and diagnostics. To learn more
about InNexus, please visit http://www.ixsbio.com/. The TSX Venture
Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this news release. This news release
may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are
subject to factors, many of which are beyond the Company's control,
that may cause actual results or performance to differ materially
from those currently anticipated in such statements. DATASOURCE:
InNexus Biotechnology Inc. CONTACT: Jeff Morhet, Chairman &
Chief Executive Officer of InNexus Biotechnology Inc.,
+1-480-862-7500 Web Site: http://www.ixsbio.com/
Copyright